MyOme is a biotechnology company specializing in clinical-grade whole genome sequencing to provide a comprehensive picture of disease risk. The company serves families and individuals looking to understand their genetic predispositions to both common and rare diseases. Operating in the genomics and personalized medicine market, MyOme combines advanced machine learning and AI technologies to generate integrated disease risk scores that evolve with lifestyle changes. The business model revolves around offering a single, detailed genetic test that delivers actionable insights over a lifetime, thereby enabling earlier health interventions and better disease management. Revenue is generated through the sale of these genetic tests and associated health insights.

Keywords: genomics, personalized medicine, disease risk, whole genome sequencing, AI, machine learning, health intervention, genetic predispositions, clinical-grade, actionable insights.